These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

187 related items for PubMed ID: 31393129

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Effect of Crohn's Disease on Villous Length and CYP3A4 Expression in the Pediatric Small Intestine.
    Vyhlidal CA, Chapron BD, Ahmed A, Singh V, Casini R, Shakhnovich V.
    Clin Transl Sci; 2021 Mar; 14(2):729-736. PubMed ID: 33278326
    [Abstract] [Full Text] [Related]

  • 5. Cytochrome P450 3A4 and P-glycoprotein expression in human small intestinal enterocytes and hepatocytes: a comparative analysis in paired tissue specimens.
    von Richter O, Burk O, Fromm MF, Thon KP, Eichelbaum M, Kivistö KT.
    Clin Pharmacol Ther; 2004 Mar; 75(3):172-83. PubMed ID: 15001968
    [Abstract] [Full Text] [Related]

  • 6. Variation in oral clearance of saquinavir is predicted by CYP3A5*1 genotype but not by enterocyte content of cytochrome P450 3A5.
    Mouly SJ, Matheny C, Paine MF, Smith G, Lamba J, Lamba V, Pusek SN, Schuetz EG, Stewart PW, Watkins PB.
    Clin Pharmacol Ther; 2005 Dec; 78(6):605-18. PubMed ID: 16338276
    [Abstract] [Full Text] [Related]

  • 7. The consequence of regional gradients of P-gp and CYP3A4 for drug-drug interactions by P-gp inhibitors and the P-gp/CYP3A4 interplay in the human intestine ex vivo.
    Li M, de Graaf IA, van de Steeg E, de Jager MH, Groothuis GM.
    Toxicol In Vitro; 2017 Apr; 40():26-33. PubMed ID: 27939799
    [Abstract] [Full Text] [Related]

  • 8. Unmasking the dynamic interplay between intestinal P-glycoprotein and CYP3A4.
    Cummins CL, Jacobsen W, Benet LZ.
    J Pharmacol Exp Ther; 2002 Mar; 300(3):1036-45. PubMed ID: 11861813
    [Abstract] [Full Text] [Related]

  • 9. Effect of variations in the amounts of P-glycoprotein (ABCB1), BCRP (ABCG2) and CYP3A4 along the human small intestine on PBPK models for predicting intestinal first pass.
    Bruyère A, Declèves X, Bouzom F, Ball K, Marques C, Treton X, Pocard M, Valleur P, Bouhnik Y, Panis Y, Scherrmann JM, Mouly S.
    Mol Pharm; 2010 Oct 04; 7(5):1596-607. PubMed ID: 20604570
    [Abstract] [Full Text] [Related]

  • 10. P-glycoprotein and cytochrome P450 3A act together in restricting the oral bioavailability of paclitaxel.
    Hendrikx JJ, Lagas JS, Rosing H, Schellens JH, Beijnen JH, Schinkel AH.
    Int J Cancer; 2013 May 15; 132(10):2439-47. PubMed ID: 23090875
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Overexpression of P-glycoprotein, MRP2, and CYP3A4 impairs intestinal absorption of octreotide in rats with portal hypertension.
    Sun X, Tang S, Hou B, Duan Z, Liu Z, Li Y, He S, Wang Q, Chang Q.
    BMC Gastroenterol; 2021 Jan 06; 21(1):2. PubMed ID: 33407159
    [Abstract] [Full Text] [Related]

  • 18. PXR/CYP3A4-humanized mice for studying drug-drug interactions involving intestinal P-glycoprotein.
    Holmstock N, Gonzalez FJ, Baes M, Annaert P, Augustijns P.
    Mol Pharm; 2013 Mar 04; 10(3):1056-62. PubMed ID: 23360470
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.